Professor Richard Hindley
Consultant Urologist
- Available from
- London
About Richard Hindley
Appointed as a Consultant Urologist in 2004, and working as a key consultant at our Private Men's Health Clinic in London, following a fellowship in Brisbane in 2003. Initially appointed as a laparoscopic surgeon for upper urinary tract malignancy and prostate cancer diagnostics and BPH. Within 2 years of his appointment, he had introduced the Greenlight laser procedure for men with benign prostate problems as well as HIFU treatment for prostate cancer. Always interested in research and innovation Richard has collaborated closely with UCLH, Imperial and Oxford Universities. He was a key member of the team working with the MRC to set up and recruit to the groundbreaking PROMIS trial which has forever changed the diagnostic pathway for men with suspected prostate cancer with the incorporation of multiparametric MRI as the triage tool prior to biopsy. Increasingly the majority of his work both clinical and academic is focussed on the prostate. He has now published over 100 predominantly prostate related publications in the urological literature. In 2017 he was awarded a visiting professor position at the University of Winchester in recognition of this. He is currently working on a project to improve decision-making for men facing a multitude of treatment options for benign prostate problems.
In early 2017 he performed the first UK cases of Rezum water vapour therapy for men with symptoms due to benign prostate enlargement, and is now a recognised key opinion leader in the field of minimally invasive prostate treatments with experience of the majority of treatment options currently available. He is also one of very few urologists in Europe to have approaching 15 years of experience of focal therapy for prostate cancer. He is currently working on projects to try and reduce the National waiting list for men waiting for BPH treatments, and he has just recently received a research grant of £1M to investigate further the use of prostate AI in collaboration with Lucida Medical.
Expertise
- Prostate Cancer
- Symptoms due to Benign Prostate Enlargement (BPH)
- Greenlight Laser
- Rezum
- Focal Therapy for Prostate Cancer
- Minimally Invasive Treatments for Men with Symptomatic BPH
- Aquablation and Transperineal Fusion Guided Prostate Biopsies.
- Prostatitis
Overview
- Age of patients seen
- 18+
- Languages spoken
- English
- Online profiles
- Research highlights
Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience. Habashy D, Reddy D, Peters M, Shah TT, van Son M, van Rossum PSN, Tanaka MB, Cullen E, Engle R, McCracken S, Greene D, Hindley RG, Emara A, Nigam R, Orczyk C, Shergill I, Persad R, Virdi J, Moore CM, Arya M, Winkler M, Emberton M, Ahmed HU, Dudderidge T. J Urol. 2023 Jul;210(1):108-116. doi: 10.1097/JU.0000000000003443. Epub 2023 Apr 4. PMID: 37014172
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M; PROMIS study group. Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20. PMID: 28110982 Free article.
Minimally invasive surgery for benign prostatic obstruction: new insights and future technical standards. Rijo E, Hindley R, Tabatabaei S, Bach T. Curr Opin Urol. 2021 Sep 1;31(5):461-467. doi: 10.1097/MOU.0000000000000918. PMID: 34231545 Review.
Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia. Whiting D, Noureldin M, Abdelmotagly Y, Johnston MJ, Brittain J, Rajkumar G, Emara A, Hindley R. Eur Urol Open Sci. 2022 Apr 7;39:72-78. doi: 10.1016/j.euros.2022.03.006. eCollection 2022 May. PMID: 35528787 Free PMC article.
Reaching a Tipping Point: A Qualitative Exploration of Quality of Life and Treatment Decision-Making in People Living With Benign Prostatic Hyperplasia. Husted M, Gray D, Golding SE, Hindley R. Qual Health Res. 2022 Nov;32(13):1979-1992. doi: 10.1177/10497323221129262. Epub 2022 Sep 26.PMID: 36154347 Free PMC article.
- Professional memberships
British Association of Urological Surgeons (BAUS)
European Association of Urology (EAU)
British Medical Association (BMA)
Consultations and services
- Self-pay available from £325
- Health insurance
- Self-pay available from £210
- Health insurance
Insurers covered
- +4 more
- Allianz Partners
- Cigna International
- Healix
- Henner
Tests & treatments
Conditions & symptoms
Locations
Loading
Frequently asked questions
Yes, but only for certain services. Some consultations, assessments, and treatments can be booked directly, while others require a GP or specialist referral. Please check the relevant service page for guidance, and contact the centre if you’re unsure.
We aim to offer appointments as quickly as possible, and many services have same-day or next-day availability. Waiting times vary depending on the appointment type, specialty, and consultant availability, but our team will always offer the earliest suitable appointment.
Yes. You can arrange an appointment for a family member, or someone you care for, just let us know when you get in touch. We’ll need their details and consent to complete the booking, unless you're their legal guardian or have power of attorney.
Your first consultation includes a detailed discussion of your symptoms, medical history, and lifestyle factors, followed by a thorough examination. It’s helpful if you can bring the results of any previous investigations with you, as well as a list of your current medications. Come with a comfortably full bladder so you can provide a urine sample if requested.